François Meyer
Nessuna posizione attualmente
Provenienza dei contatti di primo grado di François Meyer
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
University of Zurich
38
| College/University | Other Consumer Services | 38 |
Swiss Federal Institute of Technology
27
| College/University | Other Consumer Services | 27 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands.
16
| Extinct | Miscellaneous Commercial Services | 16 |
12
| Public Company | Biotechnology | 12 |
Systemix, Inc.
 Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million.
9
| Extinct | Medical/Nursing Services | 9 |
Rhone Poulenc Rorer
 Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products.
7
| Subsidiary | Chemicals: Specialty | 7 |
Sandoz Pharmaceuticals AG
 Sandoz Pharmaceuticals AG BiotechnologyHealth Technology Sandoz Pharmaceuticals AG develops and produces biopharmaceuticals. The firm specializes in the production of biopharmaceutical and biosimilars for the treatment and prevention of chronic diseases. It focuses on finding cure for diseases, such as cancer, multiple sclerosis, rheumatoid arthritis, and inherited metabolic disorders. The company was founded on January 6, 2006 and is headquartered in Rotkreuz, Switzerland.
4
| Subsidiary | Biotechnology | 4 |
2
| Private Company | Movies/Entertainment | 2 |
BASF Performance Products Ltd. (United Kingdom)
 BASF Performance Products Ltd. (United Kingdom) Chemicals: SpecialtyProcess Industries Basf Performance Products Ltd. manufactures chemical products. It offers dyes and pigments, plastics, and other inorganic basic chemicals. The company was founded on September 12, 1996 and is headquartered in Cheadle, the United Kingdom.
2
| Subsidiary | Chemicals: Specialty | 2 |
Centre National de la Recherche Scientifique
 Centre National de la Recherche Scientifique General GovernmentGovernment Centre National de la Recherche Scientifique provides scientific research services. The firm engages in the research capable of advancing knowledge and bringing social, cultural, and economic benefits for society. The company was founded in 1939 and is headquartered in Paris, France.
1
| Government | General Government | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a François Meyer tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| UBS | Investment Managers | Corporate Officer/Principal Chairman General Counsel Director of Finance/CFO | |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Biotechnology | Chief Executive Officer Director/Board Member | |
| EDMOND DE ROTHSCHILD (SUISSE) S.A. | Financial Conglomerates | Director of Finance/CFO Director/Board Member | |
| Stanford University | College/University | Masters Business Admin Undergraduate Degree | |
Credit Suisse AG
 Credit Suisse AG Investment ManagersFinance Credit Suisse AG is an investment management firm headquartered in Zurich, Switzerland. The firm was founded in 1856 and was acquired by UBS Group AG (SWX: UBSG) from Credit Suisse Group AG in 2023. Credit Suisse manages global and regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals worldwide. They also offer private banking and wealth management, investment banking, and corporate and business support services. | Investment Managers | Corporate Officer/Principal Corporate Officer/Principal | |
| LONZA GROUP AG | Pharmaceuticals: Major | Director/Board Member Chairman | |
| ZUGER KANTONALBANK | Regional Banks | President Director/Board Member | |
Precious Woods Holding AG
 Precious Woods Holding AG Forest ProductsNon-Energy Minerals Precious Woods Holding AG produces and sells logs and sawn timber. The firm also engages in the sustainable management and use of tropical forest. It operates through the following segments: Sustainable Forestry in Brazil, Sustainable Forestry in Gabon, Trading and Carbon and Energy. The Sustainable Forestry in Brazil segment engages in the sustainable management of tropical forests and the processing of tropical timber in Brazil. The Sustainable Forestry in Gabon segment operates in the sustainable management of tropical forests and the processing of tropical timber in Gabon. The Trading segment engages in the trading of timber from external sources in Switzerland. The Carbon & Energy segment engages in the trading of certified emission reductions. The company was founded on December 17, 1990 and is headquartered in Zug, Switzerland. | Forest Products | Director/Board Member Chairman Director/Board Member | |
Sandoz AG
 Sandoz AG Pharmaceuticals: GenericHealth Technology Part of Novartis AG, Sandoz AG is a Swiss company that develops generic medicines and biosimilars. The company is based in Basel, Switzerland. | Pharmaceuticals: Generic | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
LCF Communication S.A.
 LCF Communication S.A. Investment ManagersFinance LCF Communication SA provides wealth management services. Its services include banking, asset management, and advisory services. LCF was founded by Baron Edmond de Rothschild in 1953 and is headquartered in Geneva, Switzerland. | Investment Managers | Comptroller/Controller/Auditor Corporate Officer/Principal | |
Energie 360 Grad AG
 Energie 360 Grad AG Gas DistributorsUtilities Energie 360 Grad AG engages in the distribution of natural gas and wooden pellets. The firm invests, constructs, and operates facilities for the use of renewable energies. It also offers solutions and consulting services in the areas of heating, solar energy, water supply, electricity generation and network services. The company was founded in 1998 and is headquartered in Zurich, Switzerland. | Gas Distributors | Director/Board Member Director/Board Member | |
| Massachusetts Institute of Technology | College/University | Graduate Degree Doctorate Degree | |
| The University of Chicago | College/University | Undergraduate Degree Graduate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Corporate Officer/Principal | |
| University of St. Gallen | College/University | Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal | |
| University of Amsterdam | College/University | Doctorate Degree Undergraduate Degree | |
| University of Copenhagen | College/University | Doctorate Degree Graduate Degree | |
| University of Groningen | College/University | Doctorate Degree Undergraduate Degree | |
| University of Basel | College/University | Director/Board Member Doctorate Degree Graduate Degree Doctorate Degree Corporate Officer/Principal | |
| University of Fribourg | College/University | Graduate Degree Undergraduate Degree | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Private Equity Investor Founder | |
| BANK LINTH LLB | Regional Banks | President Director/Board Member | |
Kein & Aber AG
 Kein & Aber AG Publishing: Books/MagazinesConsumer Services Kein & Aber AG engages in publishing books. It publishes books, pocketbooks, electronic books, digital versatile disc's, gift books, and pics and picks. The company was founded by Peter George Haag on June 26, 1992 and is headquartered in Zurich, Switzerland. | Publishing: Books/Magazines | Chairman Director/Board Member | |
Oxyrane UK Ltd.
 Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Stiftung Avenir Suisse
 Stiftung Avenir Suisse Investment Trusts/Mutual FundsMiscellaneous Stiftung Avenir Suisse develops ideas for the sociopolitical and economic development of Switzerland. It comprises of companies and private individuals from all economic branches and regions of Switzerland. The company was founded in 1999 and is headquartered in Zurich, Switzerland. | Investment Trusts/Mutual Funds | Director/Board Member Chairman Director/Board Member | |
Economiesuisse
 Economiesuisse Medical/Nursing ServicesHealth Services Economiesuisse operates as a trade industry association. The company is headquartered in Zurich, Switzerland. | Medical/Nursing Services | Director/Board Member President | |
| Mercuri Urval AG | Director/Board Member Director/Board Member | ||
| PAX Wohnbauten AG | Chief Executive Officer Director/Board Member | ||
| BKS Advokatur Notariat | Founder Founder | ||
| Spiess & Partner | Corporate Officer/Principal General Counsel | ||
| PAX-Liegenschaften AG | Chairman Director/Board Member | ||
| PAX Immotrade AG | Chief Executive Officer Director/Board Member | ||
| PAX Invest AG | Chairman Director/Board Member | ||
| PAX Real Estate AG | Chairman Director/Board Member | ||
| PAX Construct AG | Chairman Director/Board Member | ||
| Immotest Bau- & Verwaltungs-AG | Director/Board Member Chairman | ||
| REPLIMUNE GROUP, INC. | Biotechnology | Founder Director/Board Member | |
| Oxyrane, Ltd. | Chairman Director/Board Member | ||
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Founder Chairman |
Statistiche
Distribuzione geografica
| Svizzera | 33 |
| Stati Uniti | 9 |
| Paesi Bassi | 5 |
| Francia | 2 |
| Danimarca | 2 |
Settori
| Finance | 13 |
| Health Technology | 11 |
| Consumer Services | 11 |
| Non-Energy Minerals | 3 |
| Miscellaneous | 3 |
Posizioni
| Director/Board Member | 534 |
| Corporate Officer/Principal | 241 |
| Chairman | 177 |
| Chief Executive Officer | 71 |
| Independent Dir/Board Member | 63 |
Contatti più connessi
| Insiders | |
|---|---|
| Patrick K. Oesch | 43 |
| Ralph Max Büchi | 41 |
| Ernst Brugger | 35 |
| Hugo Slootweg | 34 |
| Niklaus Peter Nüesch | 29 |
| Steven Holtzman | 28 |
| Max E. Link | 28 |
| Ferdinand Verdonck | 25 |
| Rudolf Wehrli | 25 |
| Jean Bizzari | 24 |
| Heinrich Andreas Baumann | 24 |
| Thomas Wetzel | 23 |
| Joseph Feczko | 23 |
| Antonio Matteo Taormina | 22 |
| Bernhard M. Hammer | 20 |
- Borsa valori
- Insiders
- François Meyer
- Connessioni Società
